Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
665 ARTÍCULOS , VIENDO DEL 1 AL 15
The Implication of Glial Metabotropic Glutamate Receptors in Alzheimer's Disease
de Lima IBQ, Ribeiro FM.
Curr Neuropharmacol. 2023;21(2):164-182. doi: 10.2174/1570159X20666211223140303.
The Current Evidence for the Therapeutic Role of Curcumin in Alzheimer's Disease
Bland AR, Ashton JC, Kamal MA, Sahebkar A.
CNS Neurol Disord Drug Targets. 2023;22(3):318-320. doi: 10.2174/1871527321666220119105836.
Impact of the Cannabinoid System in Alzheimer's Disease
Li S, Huang Y, Yu L, Ji X, Wu J.
Curr Neuropharmacol. 2023;21(3):715-726. doi: 10.2174/1570159X20666220201091006.
Selenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer's Disease
Barbosa FAR, Canto RFS, Teixeira KF, de Souza AS, de Oliveira AS, Braga AL.
Curr Med Chem. 2023;30(6):689-700. doi: 10.2174/0929867329666220224161454.
Epigenetic Modifications by Estrogen and Androgen in Alzheimer's Disease
Kumar R, Fatima F, Yadav G, Singh S, Haldar S, Alexiou A, Ashraf GM.
CNS Neurol Disord Drug Targets. 2023;22(1):6-17. doi: 10.2174/1871527321666220225110501.
Martins GL, Ferreira CN, Palotás A, Rocha NP, Reis HJ.
Curr Neuropharmacol. 2023;21(2):202-212. doi: 10.2174/1570159X20666220327215245.
Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease
Unnisa A, Greig NH, Kamal MA.
Curr Med Chem. 2023;30(3):255-270. doi: 10.2174/0929867329666220328125206.
Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review
Mathew A, Balaji E V, Pai SRK, Kishore A, Pai V, Pemmireddy R, K S C.
CNS Neurol Disord Drug Targets. 2023;22(2):255-275. doi: 10.2174/1871527321666220401124719.
Gurram PC, Manandhar S, Satarker S, Mudgal J, Arora D, Nampoothiri M.
CNS Neurol Disord Drug Targets. 2023;22(4):539-557. doi: 10.2174/1871527321666220413090541.
The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer's Disease
Wang Y.
CNS Neurol Disord Drug Targets. 2023;22(4):577-598. doi: 10.2174/1871527321666220417005115.
Alasmari F, Alotaibi FM, Al-Qahtani WS, AlAsmari AF, Alqahtani F.
CNS Neurol Disord Drug Targets. 2023;22(5):736-744. doi: 10.2174/1871527321666220418125057.
Current Trends in the Animal Models for Screening of Nootropic Agents: A Systematic Review
Grover S, Jain S.
Curr Rev Clin Exp Pharmacol. 2023;18(3):255-269. doi: 10.2174/2772432817666220425121323.
Berberine: Is it a Promising Agent for Mental Disorders Treatment?
Shayganfard M.
Curr Mol Pharmacol. 2023;16(3):307-320. doi: 10.2174/1874467215666220509213122.
The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease
Ravikumar M, Mohan S, Velpandian C.
Curr Drug Saf. 2023;18(3):284-296. doi: 10.2174/1574886317666220517125644.
Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease
Sharma P, Babbar R, Sharma T, Madaan P, Arora S, Badavath VN.
Mini Rev Med Chem. 2023;23(1):53-66. doi: 10.2174/1389557522666220524090354.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.